1. Home
  2. NEO vs MNKD Comparison

NEO vs MNKD Comparison

Compare NEO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEO
  • MNKD
  • Stock Information
  • Founded
  • NEO 2001
  • MNKD 1991
  • Country
  • NEO United States
  • MNKD United States
  • Employees
  • NEO N/A
  • MNKD N/A
  • Industry
  • NEO Precision Instruments
  • MNKD Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEO Health Care
  • MNKD Health Care
  • Exchange
  • NEO Nasdaq
  • MNKD Nasdaq
  • Market Cap
  • NEO 2.3B
  • MNKD 1.9B
  • IPO Year
  • NEO 1999
  • MNKD 2004
  • Fundamental
  • Price
  • NEO $14.18
  • MNKD $6.04
  • Analyst Decision
  • NEO Strong Buy
  • MNKD Buy
  • Analyst Count
  • NEO 10
  • MNKD 6
  • Target Price
  • NEO $20.56
  • MNKD $8.92
  • AVG Volume (30 Days)
  • NEO 1.2M
  • MNKD 2.5M
  • Earning Date
  • NEO 02-18-2025
  • MNKD 02-25-2025
  • Dividend Yield
  • NEO N/A
  • MNKD N/A
  • EPS Growth
  • NEO N/A
  • MNKD N/A
  • EPS
  • NEO N/A
  • MNKD 0.08
  • Revenue
  • NEO $644,118,000.00
  • MNKD $267,200,000.00
  • Revenue This Year
  • NEO $12.98
  • MNKD $45.45
  • Revenue Next Year
  • NEO $9.94
  • MNKD $16.45
  • P/E Ratio
  • NEO N/A
  • MNKD $76.18
  • Revenue Growth
  • NEO 12.06
  • MNKD 51.35
  • 52 Week Low
  • NEO $12.13
  • MNKD $3.17
  • 52 Week High
  • NEO $19.11
  • MNKD $7.63
  • Technical
  • Relative Strength Index (RSI)
  • NEO 40.28
  • MNKD 38.99
  • Support Level
  • NEO $13.93
  • MNKD $5.79
  • Resistance Level
  • NEO $16.18
  • MNKD $6.32
  • Average True Range (ATR)
  • NEO 1.13
  • MNKD 0.20
  • MACD
  • NEO -0.33
  • MNKD -0.03
  • Stochastic Oscillator
  • NEO 29.37
  • MNKD 26.04

About NEO NeoGenomics Inc.

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: